Spots Global Cancer Trial Database for camizestrant
Every month we try and update this database with for camizestrant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | NCT06188520 | ER+ HER2- Advan... High-grade Sero... | AZD8421 Camizestrant Ribociclib Palbociclib Abemaciclib | 18 Years - | AstraZeneca | |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | NCT05774951 | Breast Cancer, ... | Camizestrant Tamoxifen Anastrozole Letrozole Exemestane | 18 Years - 130 Years | AstraZeneca | |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | NCT04644068 | Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer Additional Indi... Non-small Cell ... Colorectal Canc... Bladder Cancer Gastric Cancer Biliary Cancer Cervical Cancer Endometrial Can... Small Cell Lung... | AZD5305 Paclitaxel Carboplatin T- Dxd Dato-DXd Camizestrant | 18 Years - 130 Years | AstraZeneca | |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | NCT05952557 | Breast Cancer, ... | Camizestrant Tamoxifen Anastrozole Letrozole Exemestane Abemaciclib | 18 Years - 130 Years | AstraZeneca | |
| A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer | NCT04214288 | Advanced ER-Pos... | AZD9833 Fulvestrant | 18 Years - 130 Years | AstraZeneca | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | NCT06380751 | Advanced Breast... | Saruparib (AZD5... Camizestrant Abemaciclib Ribociclib Palbociclib Fulvestrant Letrozole Anastrozole Exemestane | 18 Years - 130 Years | AstraZeneca | |
| A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole | NCT05551897 | Healthy Subject... | Camizestrant Itraconazole | 50 Years - 70 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
